Advances in the genetics of sarcoidosis

Clinical Genetics

Volumn 73, Issue 5, 2008, Pages 401-412

  Smith, A ^a   Brownell, Isaac ^b   Sanchez, M ^c   Prystowsky, S ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Genetic predisposition to disease; Granuloma; Human leukocyte antigen; Sarcoidosis

Indexed keywords

B7 ANTIGEN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR5; COMPLEMENT COMPONENT C3B RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 15; INTERLEUKIN 16; INTERLEUKIN 4; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 1; RANTES; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNINDEXED DRUG; VITAMIN D RECEPTOR;

ANTIGEN PRESENTATION; CYTOKINE RELEASE; DISEASE COURSE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC LINKAGE; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; GENOTYPE; HIGH RISK POPULATION; HUMAN; IMMUNOPATHOGENESIS; LUNG SARCOIDOSIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SARCOIDOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE ACTIVATION;

ANIMALS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAJOR HISTOCOMPATIBILITY COMPLEX; SARCOIDOSIS;

EID: 42049099973     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2008.00970.x     Document Type: Review

References (137)

1. James DG, Sharma OP. From Hutchinson to now: A historical glimpse. Curr Opin Pulm Med 2002: 8 (5): 416-423.
2. Hutchinson J. Illustrations of clinical surgery. London: J and A Churchill, 1875.
3. Hutchinson J. Case of livid papillary psoriasis. Illustrations of clinical surgery. London: J and A Churchill, 1877: 42.
4. English JC, Patel PJ, Greer KE. Sarcoidosis. J Am Acad Dermatol 2001: 44: 725-743.
5. Rezeig MA, Fahir BM. Biliary tract obstruction due to sarcoidosis. Am J Gastroenterol 1997: 92: 527-528.
6. Kerdel FA, Moschella SL. Sarcoidosis: An updated review. J Am Acad Dermatol 1984: 11: 1-19.
7. Giuffrida TJ, Francisco AK. Sarcoidosis. Dermatol Clin 2002: 20: 425-447.
8. Rybicki BA, Major M, Popovich J Jr, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: A 5-year study in a health maintenance organization. Am J Epidemiol 1997: 145: 234-241.
9. Cancrini C, Angelini F, Colavita M et al. Erythema nodosum: A presenting sign of early onset sarcoidosis. Clin Exp Rheumatol 1998: 16: 337-339.
10. Mana J, Marcoval J, Graells J et al. Cutaneous involvement in sarcoidosis: Relationship to cutaneous disease. Arch Dermatol 1997: 133: 882-888.
11. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999: 160 (2): 736-755.
12. Rybicki BA, Iannuzzi MC, Frederick MM et al. Familial aggregation of sarcoidosis: A case-control etiologic study of sarcoidosis (ACCESS). Am J Respir Crit Care Med 2001: 164: 2085-2091.
13. ACCESS Research Group. Design of a case control etiologic study of sarcoidosis (ACCESS). J Clin Epidemiol 1999: 52 (12): 1173-1186.
14. Hunninghake GW, Crystal RG. Pulmonary sarcoidosis: A disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med 1981: 305 (8): 429-434.
15. Wahlstrom J, Berlin M, Skold CM, Wigzell H, Eklund A, Grunewald J. Phenotypic analysis of lymphocytes and monocytes/macrophages in peripheral blood and bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Thorax 1999: 54 (4): 339-346.
16. Gurrieri C, Bortoli M, Brunetta E, Piazza F, Agostini C. Cytokines, chemokines and other biomolecular markers in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005: 22 (Suppl. 1): S9-S14.
17. Agostini C, Meneghin A, Semenzato G. T-lymphocytes and cytokines in sarcoidosis. Curr Opin Pulm Med 2002: 8 (5): 435-440.
18. Devergne O, Marfaing-Koka A, Schall TJ et al. Production of the RANTES chemokine in delayed-type hypersensitivity reactions: Involvement of macrophages and endothelial cells. J Exp Med 1994: 179 (5): 1689-1694 [Erratum in J Exp Med 1994: 180 (2): 775].
19. Moller DR. Cells and cytokines involved in the pathogenesis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999: 16 (1): 24-31.
20. Brewerton DA. HLA system and rheumatic disease. J Clin Pathol Suppl (R Coll Pathol) 1978: 12: 117-119.
21. Brewerton DA, Cockburn C, James DC, James DG, Neville E. HLA antigens in sarcoidosis. Clin Exp Immunol 1977: 27 (2): 227-229.
22. Hedfors E, Lindstrom F. HLA-B8/DR3 in sarcoidosis. Correlation to acute onset disease with arthritis. Tissue Antigens 1983: 22 (3): 200-203.
23. Kunikane H, Abe S, Tsuneta Y et al. Role of HLA-DR antigens in Japanese patients with sarcoidosis. Am Rev Respir Dis 1987: 135 (3): 688-691.
24. Prasad VK, Kernan NA, Heller G, O'Reilly RJ, Yang SY. DNA typing for HLA-A and HLA-B identifies disparities between patients and unrelated donors matched by HLA-A and HLA-B serology and HLA-DRB1. Blood 1999: 93 (1): 399-409.
25. Abe S, Yamaguchi E, Makimura S, Okazaki N, Kunikane H, Kawakami Y. Association of HLA-DR with sarcoidosis. Correlation with clinical course. Chest 1987: 92 (3): 488-490.
26. Kunikane H, Abe S, Yamaguchi E et al. Analysis of restriction fragment length polymorphism for the HLA-DR gene in Japanese patients with sarcoidosis. Thorax 1994: 49 (6): 573-576.
27. Pasturenzi L, Martinetti M, Cuccia M et al. HLA class I, II, and III polymorphism in Italian patients with sarcoidosis. The Pavia-Padova Sarcoidosis Study Group. Chest 1993: 104 (4): 1170-1175.
28. Martinetti M, Tinelli C, Kolek V et al. "The sarcoidosis map": a joint survey of clinical and immunogenetic findings in two European countries. Am J Respir Crit Care Med 1995: 152 (2): 557-564.
29. Ishihara M, Ishida T, Inoko H et al. HLA serological and class II genotyping in sarcoidosis patients in Japan. Jpn J Ophthalmol 1996: 40 (1): 86-94.
30. Rossman MD, Thompson B, Frederick M et al.; ACCESS Group. HLA-DRB1*1101: A significant risk factor for sarcoidosis in blacks and whites. Am J Hum Genet 2003: 73 (4): 720-735.
31. Bogunia-Kubik K, Tomeczko J, Suchnicki K, Lange A. HLA-DRB1*03, DRB1*11 or DRB1*12 and their respective DRB3 specificities in clinical variants of sarcoidosis. Tissue Antigens 2001: 57 (1): 87-90.
32. Ishihara M, Ohno S, Ishida T et al. Molecular genetic studies of HLA class II alleles in sarcoidosis. Tissue Antigens 1994: 43 (4): 238-241.
33. Sato H, Grutters JC, Pantelidis P et al. HLA-DQB1*0201: A marker for good prognosis in British and Dutch patients with sarcoidosis. Am J Respir Cell Mol Biol 2002: 27 (4): 406-412.
34. Iannuzzi MC, Maliarik MJ, Poisson LM, Rybicki BA. Sarcoidosis susceptibility and resistance HLA-DQB1 alleles in African Americans. Am J Respir Crit Care Med 2003: 167 (9): 1225-1231.
35. Voorter CE, Drent M, van den Berg-Loonen EM. Severe pulmonary sarcoidosis is strongly associated with the haplotype HLA-DQB1*0602-DRB1*150101. Hum Immunol 2005: 66 (7): 826-835.
36. Voorter CE, Drent M, Hoitsma E, Faber KG, van den Berg-Loonen EM. Association of HLA DQB1 0602 in sarcoidosis patients with small fiber neuropathy. Sarcoidosis Vasc Diffuse Lung Dis 2005: 22 (2): 129-132.
37. Grunewald J, Eklund A, Olerup O. Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. Am J Respir Crit Care Med 2004: 169 (6): 696-702.
38. Martinetti M, Luisetti M, Cuccia M. HLA and sarcoidosis: New pathogenetic insights. Sarcoidosis Vasc Diffuse Lung Dis 2002: 19 (2): 83-95.
39. Rybicki BA, Maliarik MJ, Poisson LM, Iannuzzi MC. Sarcoidosis and granuloma genes: A family-based study in African-Americans. Eur Respir J 2004: 24 (2): 251-257.
40. Dai H, Guzman J, Chen B, Costabel U. Production of soluble tumor necrosis factor receptors and tumor necrosis factor-{alpha} by alveolar macrophages in sarcoidosis and extrinsic allergic alveolitis. Chest 2005: 127: 251-256.
41. Zheng L, Teschler H, Guzman J, Hubner K, Striz I, Costabel U. Alveolar macrophage TNF-alpha release and BAL cell phenotypes in sarcoidosis. Am J Respir Crit Care Med 1995: 152 (3): 1061-1066.
42. Pritchard C, Nadarajah K. Tumour necrosis factor {alpha} inhibitor treatment for sarcoidosis refractory to conventional treatments: A report of five patients. Ann Rheum Dis 2004: 63 (3): 318-320.
43. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005: 127 (3): 1064-1071.
44. Baughman RP, Drent M, Kavuru M et al., on behalf of the Sarcoidosis Investigators. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006: 174 (7): 795-802.
45. Wilson AG, di Giovine FS, Blakemore AI, Duff GW. Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992: 1 (5): 353.
46. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997: 34 (5): 391-399.
47. Somoskovi A, Zissel G, Seitzer U, Gerdes J, Schlaak M, Muller-Quernheim J. Polymorphisms at position -308 in the promoter region of the TNF-alpha and in the first intron of the TNF-beta genes and spontaneous and lipopolysaccharide-induced TNF-alpha release in sarcoidosis. Cytokine 1999: 11 (11): 882-887.
48. Seitzer U, Swider C, Stuber F et al. Tumour necrosis factor alpha promoter gene polymorphism in sarcoidosis. Cytokine 1997: 9 (10): 787-790.
49. Labunski S, Posern G, Ludwig S, Kundt G, Brocker EB, Kunz M. Tumour necrosis factor-alpha promoter polymorphism in erythema nodosum. Acta Derm Venereol 2001: 81 (1): 18-21.
50. Grutters JC, Sato H, Pantelidis P et al. Increased frequency of the uncommon tumor necrosis factor -857T allele in British and Dutch patients with sarcoidosis. Am J Respir Crit Care Med 2002: 165 (8): 1119-1124.
51. Wilson AG, de Vries N, Pociot F, di Giovine FS, van der Putte LB, Duff GW. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993: 177 (2): 557-560.
52. Hunninghake GW. Release of interleukin-1 by alveolar macrophages of patients with active pulmonary sarcoidosis. Am Rev Respir Dis 1984: 129 (4): 569-572.
53. Hutyrova B, Pantelidis P, Drabek J et al. Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2002: 165 (2): 148-151.
54. Niimi T, Sato S, Tomita H et al. Lack of association with interleukin 1 receptor antagonist and interleukin-1beta gene polymorphisms in sarcoidosis patients. Respir Med 2000: 94 (11): 1038-1042.
55. Grutters JC, Sato H, Pantelidis P et al. Analysis of IL6 and IL1A gene polymorphisms in UK and Dutch patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2003: 20 (1): 20-27.
56. Rengarajan J, Szabo SJ, Glimcher LH. Transcriptional regulation of Th1/ Th2 polarization. Immunol Today 2000: 21 (10): 479-483.
57. Hackstein H, Hofmann H, Bohnert A, Bein G. Definition of human interleukin-4 receptor alpha chain haplotypes and allelic association with atopy markers. Hum Immunol 1999: 60 (11): 1119-1127.
58. Beghe B, Barton S, Rorke S et al. Polymorphisms in the interleukin-4 and interleukin-4 receptor alpha chain genes confer susceptibility to asthma and atopy in a Caucasian population. Clin Exp Allergy 2003: 33 (8): 1111-1117.
59. Bohnert A, Schurmann M, Hartung A, Hackstein H, Muller-Quernheim J, Bein G. No linkage of the interleukin-4 receptor locus on chromosome 16p11.2-12.1 with sarcoidosis in German multiplex families. Eur J Immunogenet 2002: 29 (3): 269-272.
60. Yoshimoto T, Takeda K, Tanaka T et al. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: Synergism with IL-18 for IFN-gamma production. J Immunol 1998: 161 (7): 3400-3407.
61. Papaioannides D, Fotinou M, Korantzopoulos P et al. Sarcoidosis associated with interferon-alpha therapy for chronic hepatitis C. Med Sci Monit 2004: 10 (1): CS5-CS7.
62. Yavorkovsky LL, Carrum G, Bruce S, McCarthy PL Jr. Cutaneous sarcoidosis in a patient with Philadelphia-positive chronic myelogenous leukemia treated with interferon-alpha. Am J Hematol 1998: 58 (1): 80-81.
63. Akahoshi M, Ishihara M, Remus N et al. Association between IFNA genotype and the risk of sarcoidosis. Hum Genet 2004: 114: 503-509.
64. Salez F, Gosset P, Copin MC, Lamblin Degros C, Tonnel AB, Wallaert B. Transforming growth factor-beta1 in sarcoidosis. Eur Respir J 1998: 12 (4): 913-919.
65. Murakozy G, Gaede KI, Zissel G, Schlaak M, Muller-Quernheim J. Analysis of gene polymorphisms in interleukin-10 and transforming growth factor-beta 1 in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001: 18 (2): 165-169.
66. Niimi T, Sato S, Sugiura Y et al. Transforming growth factor-beta gene polymorphism in sarcoidosis and tuberculosis patients. Int J Tuberc Lung Dis 2002: 6 (6): 510-515.
67. Kruit A, Grutters JC, Ruven HJ et al. Transforming growth factor-beta gene polymorphisms in sarcoidosis patients with and without fibrosis. Chest 2006: 129 (6): 1584-1591.
68. Akira A, Takeda K, Kaisho T. Toll-like receptors: Critical proteins linking innate and acquired immunity. Nat Immunol 2001: 2: 675-680.
69. Pabst S, Baumgarten G, Stremmel A et al. Toll-like receptor (TLR) 4 polymorphisms are associated with a chronic course of sarcoidosis. Clin Exp Immunol 2006: 143 (3): 420-426.
70. Veltkamp M, Grutters JC, van Moorsel CH, Ruven HJ, van den Bosch JM. Toll-like receptor (TLR) 4 polymorphism Asp299Gly is not associated with disease course in Dutch sarcoidosis patients. Clin Exp Immunol 2006: 145 (2): 215-218.
71. Harrell GT, Fisher S. Blood chemical changes in Boeck's sarcoid with particular reference to protein, calcium and phosphatase values. J Clin Invest 1939: 18: 687-693.
72. Braun J, Dinkelacker C, Bohnet S, Kreft B, Dalhoff K. 1,25-dihydroxycholecalciferol stimulates ICAM-1 expression of human alveolar macrophages in healthy controls and patients with sarcoidosis. Lung 1999: 177 (3): 139-149.
73. Guleva I, Seitzer U. Vitamin D receptor gene polymorphism in patients with sarcoidosis. Am J Respir Crit Care Med 2000: 162 (2 Pt 1): 760-761.
74. Grutters JC. Genetics of sarcoidosis: Role of co-stimulatory genes? Respiration 2005: 72 (3): 227-228.
75. Nicod LP, Isler P. Alveolar macrophages in sarcoidosis coexpress high levels of CD86 (B7.2), CD40, and CD30L. Am J Respir Cell Mol Biol 1997: 17 (1): 91-96.
76. Handa T, Nagai S, Ito I et al. Polymorphisms of B7 (CD80 and CD86) genes do not affect disease susceptibility to sarcoidosis. Respiration 2005: 72 (3): 243-248.
77. Valentonyte R, Hampe J, Huse K et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nat Genet 2005: 37 (4): 357-364.
78. Rybicki BA, Walewski JL, Maliarik MJ, Kian H, Iannuzzi MC; ACCESS Research Group. The BTNL2 gene and sarcoidosis susceptibility in African Americans and Whites. Am J Hum Genet 2005: 77 (3): 491-499.
79. Li Y, Wollnik B, Pabst S et al. BTNL2 gene variant and sarcoidosis. Thorax 2006: 61 (3): 273-274.
80. Bombieri C, Luisetti M, Belpinati F et al. Increased frequency of CFTR gene mutations in sarcoidosis: A case/control association study. Eur J Hum Genet 2000: 8 (9): 717-720.
81. Bombieri C, Belpinati F, Pignatti PF, Luisetti M. Comment on 'CFTR gene mutations in sarcoidosis'. Eur J Hum Genet 2003: 11 (8): 553-554.
82. Schurmann M, Albrecht M, Schwinger E, Stuhrmann M. CFTR gene mutations in sarcoidosis. Eur J Hum Genet 2002: 10 (11): 729-732.
83. Zorzetto M, Bombieri C, Ferrarotti I et al. Complement receptor 1 gene polymorphisms in sarcoidosis. Am J Respir Cell Mol Biol 2002: 27 (1): 17-23.
84. Preobrazhensky AA, Dragan S, Kawano T et al. Monocyte chemotactic protein-1 receptor CCR2B is a glycoprotein that has tyrosine sulfation in a conserved extracellular N-terminal region. J Immunol 2000: 165 (9): 5295-5303.
85. Hizawa N, Yamaguchi E, Furuya K, Jinushi E, Ito A, Kawakami Y. The role of the C-C chemokine receptor 2 gene polymorphism V64I (CCR2-64I) in sarcoidosis in a Japanese population. Am J Respir Crit Care Med 1999: 159 (6): 2021-2023.
86. Petrek M, Drabek J, Kolek V et al. CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. Am J Respir Crit Care Med 2000: 162 (3 Pt 1): 1000-1003.
87. Spagnolo P, Renzoni EA, Wells AU et al. C-C chemokine receptor 2 and sarcoidosis: Association with Lofgren's syndrome. Am J Respir Crit Care Med 2003: 168 (10): 1162-1166.
88. Valentonyte R, Hampe J, Croucher PJ et al. Study of C-C chemokine receptor 2 alleles in sarcoidosis, with emphasis on family-based analysis. Am J Respir Crit Care Med 2005: 171 (10): 1136-1141.
89. Samson M, LaRosa G, Libert F et al. The second extracellular loop of CCR5 is the major determinant of ligand specificity. J Biol Chem 1997: 272 (40): 24934-24941.
90. Standiford TJ, Rolfe MW, Kunkel SL et al. Macrophage inflammatory protein-1 alpha expression in interstitial lung disease. J Immunol 1993: 151 (5): 2852-2863.
91. Hashimoto S, Nakayama T, Gon Y et al. Correlation of plasma monocyte chemoattractant protein-1 (MCP-1) and monocyte inflammatory protein-1alpha (MIP-1alpha) levels with disease activity and clinical course of sarcoidosis. Clin Exp Immunol 1998: 111 (3): 604-610.
92. Petrek M, Kolek V, Szotkowska J, du Bois RM. CC and C chemokine expression in pulmonary sarcoidosis. Eur Respir J 2002: 20 (5): 1206-1212.
93. Takada T, Suzuki E, Morohashi K, Omori K, Gejyo F. MCP-1 and MIP-1A gene polymorphisms in Japanese patients with sarcoidosis. Intern Med 2002: 41 (10): 813-818.
94. Petrek M, Gibejova A, Drabek J et al. CC chemokine receptor 5 (CCR5) mRNA expression in pulmonary sarcoidosis. Immunol Lett 2002: 80 (3): 189-193.
95. Capelli A, Di Stefano A, Lusuardi M, Gnemmi I, Donner CF. Increased macrophage inflammatory protein-1alpha and macrophage inflammatory protein-1beta levels in bronchoalveolar lavage fluid of patients affected by different stages of pulmonary sarcoidosis. Am J Respir Crit Care Med 2002: 165 (2): 236-241.
96. Spagnolo P, Renzoni EA, Wells AU et al. C-C chemokine receptor 5 gene variants in relation to lung disease in sarcoidosis. Am J Respir Crit Care Med 2005: 172 (6): 721-728.
97. Perkins ND. The Rel/NF-kappa B family: Friend and foe. Trends Biochem Sci 2000: 25 (9): 434-440.
98. Drent M, van den Berg R, Haenen GR, van den Berg H, Wouters EF, Bast A. NF-kappaB activation in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001: 18 (1): 50-56.
99. Abdallah A, Sato H, Grutters JC et al. Inhibitor kappa B-alpha (IkappaB-alpha) promoter polymorphisms in UK and Dutch sarcoidosis. Genes Immun 2003: 4 (6): 450-454.
100. Girardin SE, Boneca IG, Viala J et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003: 278 (11): 8869-8872.
101. Kanazawa N, Okafuji I, Kambe N et al. Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: Common genetic etiology with Blau syndrome. Blood 2005: 105 (3): 1195-1197.
102. Tanabe T, Ishige I, Suzuki Y et al. Sarcoidosis and NOD1 variation with impaired recognition of intracellular Propionibacterium acnes. Biochim Biophys Acta 2006: 1762 (9): 794-801.
103. Schurmann M, Valentonyte R, Hampe J, Muller-Quernheim J, Schwinger E, Schreiber S. CARD15 gene mutations in sarcoidosis. Eur Respir J 2003: 22 (5): 748-754.
104. Martin TM, Doyle TM, Smith JR, Dinulescu D, Rust K, Rosenbaum JT. Uveitis in patients with sarcoidosis is not associated with mutations in NOD2 (CARD15). Am J Ophthalmol 2003: 136 (5): 933-935.
105. Ho LP, Merlin F, Gaber K, Davies RJ, McMichael AJ, Hugot JP. CARD 15 gene mutations in sarcoidosis. Thorax 2005: 60 (4): 354-355.
106. Milman N, Nielsen OH, Hviid TV, Fenger K. CARD15 single nucleotide polymorphisms 8, 12 and 13 are not increased in ethnic Danes with sarcoidosis. Respiration 2007: 74: 76-79.
107. Rybicki BA, Maliarik MJ, Bock CH et al. The Blau syndrome gene is not a major risk factor for sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999: 16: 203-208.
108. Multhoff G, Botzler C. Heat-shock proteins and the immune response. Ann N Y Acad Sci 1998: 30 (851): 86-93.
109. de Smet MD, Ramadan A. Circulating antibodies to inducible heat shock protein 70 in patients with uveitis. Ocul Immunol Inflamm 2001: 9 (2): 85-92.
110. Hrycaj P, Wurm K, Mennet P, Muller W. Antibodies to heat shock proteins in patients with pulmonary sarcoidosis. Sarcoidosis 1995: 12 (2): 124-130.
111. Ishihara M, Ohno S, Ishida T et al. Genetic polymorphisms of the TNFB and HSP70 genes located in the human major histocompatibility complex in sarcoidosis. Tissue Antigens 1995: 46 (1): 59-62.
112. Antoniou KM, Tzouvelekis A, Alexandrakis MG et al. Different angiogenic activity in pulmonary sarcoidosis and idiopathic pulmonary fibrosis. Chest 2006: 130 (4): 982-988.
113. Meyer KC, Kaminski MJ, Calhoun WJ et al. Studies of bronchoalveolar lavage cells and fluids in pulmonary sarcoidosis: I. Enhanced capacity of bronchoalveolar lavage cells from patients with pulmonary sarcoidosis to induce angiogenesis in vivo. Am Rev Respir Dis 1989: 140: 1446-1449.
114. Tolnay E, Kuhnen C, Voss B et al. Expression and localization of vascular endothelial growth factor and its receptor flt in pulmonary sarcoidosis. Virchows Arch 1998: 432: 61-65.
115. Morohashi K, Takada T, Omori K, Suzuki E, Gejyo F. Vascular endothelial growth factor gene polymorphisms in Japanese patients with sarcoidosis. Chest 2003: 123 (5): 1520-1526.
116. Iannuzzi MC. Clara cell protein in sarcoidosis: Another job for the respiratory tract protector? Am J Respir Crit Care Med 2004: 169 (2): 143-144.
117. Shijubo N, Itoh Y, Shigehara K et al. Association of Clara cell 10-kDa protein, spontaneous regression and sarcoidosis. Eur Respir J 2000: 16 (3): 414-419.
118. Ohchi T, Shijubo N, Kawabata I et al. Polymorphism of Clara cell 10-kD protein gene of sarcoidosis. Am J Respir Crit Care Med 2004: 169 (2): 180-186.
119. Janssen R, Sato H, Grutters JC et al. The Clara cell10 adenine38guanine polymorphism and sarcoidosis susceptibility in Dutch and Japanese subjects. Am J Respir Crit Care Med 2004: 170 (11): 1185-1187.
120. Maliarik MJ, Chen KM, Sheffer RG et al. The natural resistance-associated macrophage protein gene in African Americans with sarcoidosis. Am J Respir Cell Mol Biol 2000: 22 (6): 672-675.
121. Dubaniewicz A, Jamieson SE, Dubaniewicz-Wybieralska M, Fakiola M, Nancy Miller E, Blackwell JM. Association between SLC11A1 (formerly NRAMP1) and the risk of sarcoidosis in Poland. Eur J Hum Genet 2005: 13 (7): 829-834.
122. Tomita H, Ina Y, Sugiura Y et al. Polymorphism in the angiotensin-converting enzyme (ACE) gene and sarcoidosis. Am J Respir Crit Care Med 1997: 156 (1): 255-259.
123. Alia P, Mana J, Capdevila O, Alvarez A, Navarro MA. Association between ACE gene I/D polymorphism and clinical presentation and prognosis of sarcoidosis. Scand J Clin Lab Invest 2005: 65 (8): 691-697.
124. Pietinalho A, Furuya K, Yamaguchi E, Kawakami Y, Selroos O. The angiotensin-converting enzyme DD gene is associated with poor prognosis in Finnish sarcoidosis patients. Eur Respir J 1999: 13 (4): 723-726.
125. Papadopoulos KI, Melander O, Orho-Melander M, Groop LC, Carlsson M, Hallengren B. Angiotensin converting enzyme (ACE) gene polymorphism in sarcoidosis in relation to associated autoimmune diseases. J Intern Med 2000: 247 (1): 71-77.
126. Schurmann M, Reichel P, Muller-Myhsok B et al. Angiotensin-converting enzyme (ACE) gene polymorphisms and familial occurrence of sarcoidosis. J Intern Med 2001: 249 (1): 77-83.
127. McGrath DS, Foley PJ, Petrek M et al. Ace gene I/D polymorphism and sarcoidosis pulmonary disease severity. Am J Respir Crit Care Med 2001: 164 (2): 197-201.
128. Maliarik MJ, Rybicki BA, Malvitz E et al. Angiotensin-converting enzyme gene polymorphism and risk of sarcoidosis. Am J Respir Crit Care Med 1998: 158 (5 Pt 1): 1566-1570.
129. Niimi T, Tomita H, Sato S, et al. Bronchial responsiveness and angiotensin-converting enzyme gene polymorphism in sarcoidosis patients. Chest 1998: 114 (2): 495-499.
130. Schurmann M, Reichel P, Muller-Myhsok B, Schlaak M, Muller-Quernheim J, Schwinger E. Results from a genome-wide search for predisposing genes in sarcoidosis. Am J Respir Crit Care Med 2001: 164 (5): 840-846.
131. Rybicki BA, Hirst K, Iyengar SK et al. A sarcoidosis genetic linkage consortium: The sarcoidosis genetic analysis (SAGA) study. Sarcoidosis Vasc Diffuse Lung Dis 2005: 22 (2): 115-122.
132. Gray-McGuire C, Sinha R, Iyengar S et al. Genetic characterization and fine mapping of susceptibility loci for sarcoidosis in African Americans on chromosome 5. Hum Genet 2006: 120 (3): 420-430.
133. Thompson CL, Rybicki BA, Iannuzzi MC, Elston RC, Iyengar SK, Gray-McGuire C; Sarcoidosis Genetic Analysis Consortium (SAGA). Reduction of sample heterogeneity through use of population substructure: An example from a population of African American families with sarcoidosis. Am J Hum Genet 2006: 79 (4): 606-613.
134. Tsiligianni I, Antoniou KM, Kyriakou D et al. Th1/Th2 cytokine pattern in bronchoalveolar lavage fluid and induced sputum in pulmonary sarcoidosis. BMC Pulm Med 2005: 5: 8.
135. Kucera GP, Rybicki BA, Kirkey KL et al. Occupational risk factors for sarcoidosis in African-American siblings. Chest 2003: 123 (5): 1527-1535.
136. Newman LS, Rose CS, Bresnitz EA et al.; ACCESS Research Group. A case control etiologic study of sarcoidosis: Environmental and occupational risk factors. Am J Respir Crit Care Med 2004: 170 (12): 1324-1330.
137. Iwai K, Skiguti M, Hosoda Y et al. Racial differences in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 1994: 11: 26-31.